NCT05514444View on ClinicalTrials.gov

Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

September 25, 2022

Primary Completion Date

September 18, 2025

Study Completion Date

September 18, 2025

Conditions
Advanced/Metastatic Solid TumorsNeoplasms
Interventions
BIOLOGICAL

MK-4464

MK-4464 administered as an IV infusion every three weeks according to allocation and dose escalation.

BIOLOGICAL

Pembrolizumab

Pembrolizumab 200 mg administered as an IV infusion every three weeks.

DRUG

89Zr-MK-4464

89ZR-MK-4464 administered as an IV infusion on C1D1.

Trial Locations (6)

40245

The University of Louisville, James Graham Brown Cancer Center ( Site 0100), Louisville

3109601

Rambam Health Care Campus-Oncology Division ( Site 0300), Haifa

9112001

Hadassah Medical Center-Oncology ( Site 0302), Jerusalem

M5G 2M9

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0201), Toronto

1066CX

Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0401), Amsterdam

1081HV

Amsterdam UMC, locatie VUmc ( Site 0400), Amsterdam

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY